Cardiovascular Journal of Africa: Vol 30 No 1 (January/February 2019)

CARDIOVASCULAR JOURNAL OF AFRICA • Volume 30, No 1, January/February 2019

AFRICA

we cannot exclude any beneficial effect resulting from a shorter

delay before primary PCI.

Conclusion

These data further compliment the overall INFUSE-AMI trial

results. Because the patients who received IC and IV abciximab

combined with aspiration thrombectomy had similar rates of

ST-segment resolution and MBG, we concluded that IC instead

of IV abciximab did not enhance myocardial reperfusion in

non-selected patients with STEMI undergoing primary PCI, even

after aspiration thrombectomy had successfully been performed.

Funding was provided by the Cardiology Oncology Research Collaborative

Group (CORCG), Department of Cardiology, CHU Mustapha, Faculty of

Medicine, Benyoucef Benkhedda University, Algiers, Algeria. There was no

financial relationship with industry.

References

Windecker S, Kohl P, Alfonso F,

et al

. 2014 ESC/EACTS guidelines on

myocardial revascularization.

Eur Heart J

2014;

: 2541–619.

Ibanez B, James S, Agewall S,

et al

. 2017 ESC guidelines for the

management of acute myocardial infarction in patients presenting with

ST-segment elevation: The Task Force for the management of acute

myocardial infarction in patients presenting with ST-segment elevation

of the European Society of Cardiology (ESC).

Eur Heart J

2018;

(2):

119–177.

Levine GN, Bates ER, Blankenship JC,

et al

. 2015 ACC/AHA/SCAI

focused update on primary percutaneous coronary intervention for

patients with ST-elevation myocardial infarction: an update of the 2011

ACC/AHA/SCAI guideline for percutaneous coronary intervention and

the 2013 ACCF/AHA guideline for the management of ST-elevation

myocardial infarction.

J Am Coll Cardiol

2016;

: 1235–1250.

Nijveldt R, Beck AM, Hirsch A,

et al.

Functional recovery after acute

myocardial infarction: comparison between angiography, electrocardi-

ography, and cardiovascular magnetic resonance measures of microvas-

cular injury.

J Am Coll Cardiol

2008;

: 181–189.

Schröder R. Extent of early ST-segment elevation resolution: a strong

predictor of outcome in patients with acute myocardial infarction and a

sensitive measure to compare thrombolytic regimens. A substudy of the

International Joint Efficacy Comparison of Thrombolytics (INJECT)

trial.

J Am Coll Cardiol

1995;

: 1657–1664.

Schröder R, Dissmann R, Brüggemann T,

et al

. Extent of early

ST-segment elevation resolution: a simple but strong predictor of

outcome in patients with acute myocardial infarction.

J Am Coll Cardiol

1994;

: 384–391.

Vlaar PJ, Svilaas T, van der Horst IC,

et al

. Cardiac death and re-infarc-

tion after 1 year in the Thrombus Aspiration during Percutaneous

Coronary Intervention in Acute Myocardial Infarction Study (TAPAS).

Lancet

2008;

371

: 1915–1920.

Kumbhani DJ, Bavry AA, Desai MY,

et al.

Role of aspiration and

mechanical thrombectomy in patients with acute myocardial infarction

undergoing primary angioplasty.

J Am Coll Cardiol

2013;

: 1409–1419.

Lagerqvist B, Fröbert O, Olivecrona GK,

et al

. Outcomes 1 year after

thrombus aspiration for myocardial infarction.

N Engl J Med

2014;

371

1111–1120.

10. Jolly SS, Cairns JA, Yusuf S,

et al

. Outcomes after thrombus aspiration

for ST elevation myocardial infarction: 1-year follow up of the prospec-

tive randomized TOTAL trial

. Lancet

2016;

387

: 127–135.

11. Jolly SS, James S, Dzavik V,

et al

. Thrombus aspiration in ST-segment

elevation myocardial infarction: an individual patient meta-analysis:

Thrombectomy Trialists Collaboration.

Circulation

2017;

135

: 143–152

12. Romagnoli E, Burzotta F, Trani C,

et al.

Angiographic evaluation of the

effect of intracoronary abciximab administration in patients undergoing

urgent PCI.

Int J Cardiol

2005;

105

: 250–255.

13. Prati F, Capodanno D, Pawmowski T,

et al.

Local delivery versus

intracoronary infusion of abciximab in patients with acute coronary

syndromes.

J Am Coll Cardiol Cardiovasc Interv

2010;

: 928–934.

14. De Luca G, Verdoia M, Suryapranata H. Benefits from intracoronary as

compared to intravenous abciximab administration for STEMI patients

undergoing primary angioplasty: a meta-analysis of 8 randomized trials.

Atherosclerosis

2012;

222

: 426–433.

15. Elbadawi A, Elgendy IY, Megaly M,

et al

. Meta-analysis of randomized

trials of intracoronary versus intravenous glycoprotein IIb/IIIa inhibi-

tors in patients with ST-elevation myocardial infarction undergoing

primary percutaneous coronary intervention.

Am J Cardiol

2017;

120

1055–1061.

16. Piccolo R, Eitel I, Galasso G,

et al.

One-year outcomes with intracoro-

nary abciximab in diabetic patients undergoing primary percutaneous

coronary intervention.

J Am Coll Cardiol

2016;

: 727–738.

17. Piccolo R, Eitel I, Galasso G,

et al

. Intracoronary abciximab in diabetic

patients with ST-segment elevation myocardial infarction undergoing

primary percutaneous intervention.

Vasc Pharmacol

2015;

: 32–37.

18. Stone GW, Maehara A, Witzenbichler B,

et al

. Intracoronary abciximab

and aspiration thrombectomy in patients with large anterior myocardial

infarction: the INFUSE-AMI randomized trial

. J Am Med Assoc

2012;

3017

: 1817–1826.

19. TIMI Study group. The Thrombolysis in Myocardial Infarction (TIMI)

trial, phase I findings.

N Engl J Med

1985;

312

: 932–936.

20. Van’t Hof AWJ, Liem A, Suryapranata H. Angiographic assessment of

myocardial reperfusion in patients treated with primary angioplasty for

acute myocardial infarction: myocardial blush grade.

Circulation

1998;

: 2302–2306.

21. Aitmokhtar O, Paganelli F, Benamara S,

et al.

Impact of platelet inhi-

bition level on subsequent no-reflow in patients undergoing primary

percutaneous coronary intervention for ST-segment elevation myocar-

dial infarction.

Arch Cardiovasc Dis

2017;

110

(11): 626–633.

22. Bouleti C, Mewton M, Germain S. The no-reflow phenomenon: state of

the art.

Arch Cardiovasc Dis

2015;

108

: 661–674.

23. Thygesen K, Alpert JS, Jaffe AS,

et al

. Third universal definition of

myocardial infarction.

Eur Heart J

2012;

: 2251–2267.

24. Rao AK, Pratt C, Berke A,

et al

. Thrombolysis in Myocardial Infarction

(TIMI) trial phase I: hemorrhagic manifestations and changes in plasma

fibrinogen and the fibrinolytic system in patients treated with recombi-

nant tissue plasminogen activator and streptokinase.

J Am Coll Cardiol

1988;

: 1–11.

25. Faragh EM, Al-Daydamony MM. Symptom-to-balloon time and

myocardial blush grade are predictors of left ventricular remodeling

after successful primary percutaneous intervention.

Cardiovasc J Afr

2017;

: 186–190.

26. Dominguez- Rodriguez A, Avanzas P,

et al

. Intracoronary abciximab

and local anti-inflammatory effects.

Int J Cardiol

2013;

168

: 2872.

27. Thiele H, Wohrle J, Hambrecht R,

et al

. Intracoronary versus intra-

venous bolus abciximab administration during primary percutaneous

intervention in patients with acute ST-elevation myocardial infarction: a

randomized trial.

Lancet

2012;

379

: 923–931.

28. De Rosa S, Caiazzo G, Torella D,

et al.

Intracoronary abciximab reduces

death and major adverse cardiovascular events in acute coronary

syndromes: a meta-analysis of clinical trials

. Int J Cardiol

2013;

168